Legal & General Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-9,340
| Closed | -$84.9K | – | 3455 |
|
|
2023
Q2 | $84.9K | Sell |
9,340
-34,180
| -79% | -$241K | ﹤0.01% | 2839 |
|
|
2023
Q1 | $183K | Buy |
43,520
+9,889
| +29% | +$51.3K | ﹤0.01% | 2619 |
|
|
2022
Q4 | $202K | Buy |
33,631
+23,864
| +244% | +$130K | ﹤0.01% | 2603 |
|
|
2022
Q3 | $57K | Buy |
9,767
+1,524
| +18% | +$9.5K | ﹤0.01% | 2949 |
|
|
2022
Q2 | $49K | Buy |
+8,243
| New | +$42.2K | ﹤0.01% | 3008 |
|
|
2019
Q3 | – | Sell |
-7,601
| Closed | -$7K | – | 3514 |
|
|
2019
Q2 | $7K | Hold |
7,601
| – | – | ﹤0.01% | 3427 |
|
|
2019
Q1 | $7K | Hold |
7,601
| – | – | ﹤0.01% | 3296 |
|
|
2018
Q4 | $6K | Hold |
7,601
| – | – | ﹤0.01% | 3331 |
|
|
2018
Q3 | $16K | Hold |
7,601
| – | – | ﹤0.01% | 3264 |
|
|
2018
Q2 | $38K | Buy |
+7,601
| New | +$33.3K | ﹤0.01% | 2899 |
|
|
2016
Q2 | – | Sell |
-2,698
| Closed | -$14K | – | 2991 |
|
|
2016
Q1 | $14K | Hold |
2,698
| – | – | ﹤0.01% | 2715 |
|
|
2015
Q4 | $34K | Hold |
2,698
| – | – | ﹤0.01% | 2609 |
|
|
2015
Q3 | $39K | Hold |
2,698
| – | – | ﹤0.01% | 2578 |
|
|
2015
Q2 | $53K | Hold |
2,698
| – | – | ﹤0.01% | 2518 |
|
|
2015
Q1 | $51K | Hold |
2,698
| – | – | ﹤0.01% | 2483 |
|
|
2014
Q4 | $64K | Hold |
2,698
| – | – | ﹤0.01% | 2294 |
|
|
2014
Q3 | $67K | Buy |
+2,698
| New | +$70.1K | ﹤0.01% | 2211 |
|
Legal & General Group's CTIC Position: Q3 2023 in Review
Legal & General Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q3 2023, closing a stake of 9,340 shares — an estimated $84.9K sold.
Legal & General Group first reported a position in CTIC in Q3 2014 and held it in 17 quarters. The position peaked at $202K in Q4 2022. 0 funds tracked by Wall St. Rank hold CTIC as of Q3 2023.
- Legal & General Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q3 2023 after selling out during the quarter.
- Legal & General Group sold 9,340 CTI BioPharma Corp. (DE) Common Stock shares in Q3 2023, an estimated $84.9K.
- Legal & General Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2014 and held it in 17 quarters.
- Legal & General Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $202K in Q4 2022.
- 0 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q3 2023.
Based on Legal & General Group's 13F filing for Q3 2023, filed 14 Nov 2023.